Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Liabilities and Shareholders Equity (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Liabilities and Shareholders Equity for 11 consecutive years, with $240.3 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity changed N/A to $240.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $542.0 million through Dec 2025, changed N/A year-over-year, with the annual reading at $240.3 million for FY2025, N/A changed from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $240.3 million at Crescent Biopharma, up from $138.3 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $240.3 million in Q4 2025, with the low at $6.0 million in Q1 2025.
  • Average Liabilities and Shareholders Equity over 5 years is $82.3 million, with a median of $65.0 million recorded in 2022.
  • Peak annual rise in Liabilities and Shareholders Equity hit 780.8% in 2025, while the deepest fall reached 82.48% in 2025.
  • Over 5 years, Liabilities and Shareholders Equity stood at $94.3 million in 2021, then crashed by 45.08% to $51.8 million in 2022, then decreased by 12.53% to $45.3 million in 2023, then tumbled by 65.36% to $15.7 million in 2024, then surged by 1430.71% to $240.3 million in 2025.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $240.3 million, $138.3 million, and $157.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.